确保百姓用药质优价宜

Core Viewpoint - The eleventh batch of national organized drug procurement has been initiated, focusing on 55 types of drugs, with an emphasis on ensuring quality, reasonable pricing, and meeting diverse patient needs while promoting healthy development in the pharmaceutical industry [1] Group 1: Procurement Process - The procurement process will enter the reporting phase for medical institutions, adhering to principles of "stabilizing clinical use, ensuring quality, preventing collusion, and avoiding excessive competition" [1] - The selection of drug varieties will exclude newly negotiated drugs that are still under agreement, aiming to protect industry innovation [1][2] - A total of 122 drugs met the initial selection criteria as of March 31, 2023, with 55 drugs ultimately selected for procurement [2] Group 2: Quality Assurance - Stricter quality requirements have been established, mandating that participating companies must have at least two years of production experience for similar formulations [2] - The production lines of the bidding drugs must not have violated quality management regulations in the past two years [3] - The National Medical Insurance Administration will expand real-world research to support clinical efficacy evaluations of selected drugs [2] Group 3: Pricing and Competition - The procurement rules will limit excessively low bids, requiring the lowest bidders to justify their pricing and ensure it does not fall below cost [3] - The procurement volume will generally require reporting totals to be no less than 80% of actual usage, with adjustments allowed for fluctuating clinical needs [4] - The optimization of procurement rules aims to shift the focus from "low-price competition" to "quality competition, cost control, and reasonable profits" [4]